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Prostate cancer is the most common cancer
in American men and is second worldwide
causing over 250,000 deaths per year.1
Cancer
whole-genome
and
exome
sequencing studies have shown that Speckletype POZ (pox virus and zinc finger protein)
protein (SPOP) is the most frequently mutated
gene in primary prostate cancer (PCa).1 It is
also reported that SPOP is characterized to
play a role in tumorigenesis. 2 SPOP
mutations in prostate cancer occur at a high Fig 2.
WT
frequency in a few specific residues (or
so‐called “hotspots”) in the MATH domain,
such as F133V, W131G, and F102C.3
Moreover, SPOP mutations have been
identified as an early event in the
development of genomic instability and
tumorigenesis in PCa.2
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Future Goal
Our next goal is to perform RNAsequencing
to
identify
the
downstream transcriptional factor
of SPOP which regulates histone
modification.

Method

1. Mice – For the DX1 B6 subQ model, we
subcutaneously (subQ) injected DX1 mouse
prostate cells into B6 mice and measured the
tumor volume twice a week and the tumor
weight at the end point. For the PTEN SPOP
F133V mouse model, we crossed PTEN KO
mice (P) with SPOP mutant F133V mice to
generate PTEN SPOP mutant mice (PSP)
and then crossed with Pb-Cre mice to
generate PSP prostate cancer specific PTEN
KO and SPOP mutations prostate cancer
genetic engineering mouse model (GEMM)
with green fluorescent protein reporter.
2. Transwell assay – We performed transwell
assay using 8um pore size on DU145 WT,
F102C, W131G, and F133V mutant cells to
determine cell migration ability.

3. Immunohistochemistry (IHC) – We
performed IHC on FLAG F10 (CST 14793S,
1:200), P-AKT (CST 4060S, 1:100), H3K36
(CST 4909S, 1:1600), H3K4 (CST 9751S,
1:5000) to examine protein expression levels
and localization on mouse prostate tumors.

Result
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SPOP mutation frequently occurs in
prostate cancer, here we used DX1
subQ mouse model showing that
mutant SPOP drives prostate tumor
progression in vivo, and the in vitro
data shows SPOP mutations
promote tumor migration. Thereafter,
we generated SPOP mutation
GEMM and
found that the
transcription factors related activate
H3K36me3 and H3K4me3 were
drastically upregulated in PSP mice.
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